Open AccessA Randomized Study of Quantiferon CMV-directed Versus Fixed-duration Valganciclovir Prophylaxis to Reduce Late CMV After Lung Transplantation
Author(s) -
Glen Westall,
Y. Cristiano,
B. Levvey,
Helen Whitford,
Miranda Paraskeva,
Eldho Paul,
Anton Y. Peleg,
Gregory I Snell
Publication year - 2019
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002454
Subject(s) - valganciclovir , medicine , viremia , lung transplantation , gastroenterology , incidence (geometry) , immunology , cytomegalovirus , transplantation , clinical endpoint , ganciclovir , human cytomegalovirus , randomized controlled trial , herpesviridae , virus , viral disease , physics , optics
We provide the results of the first interventional study of cytomegalovirus (CMV)-specific immune monitoring to direct the length of antiviral prophylaxis in lung transplantation (LTx).